

Group 5

The impact of precision
medicine in the management of
MBC patients in real world

Objectives

- Evaluate the impact of the molecular tumor board (MTB) recommendation on physicians' choice
- Study the adherence to MTB recommendation
- Study the outcome of MBC patients who follow MTB recommendation
- Increase the access to clinical trials (compared to hospital historical enrollment)

Scientific contest and literature

- SAFIR 01, ESCAT (Esmo scale for clinical actionability of molecular targets), NTRK fusions (Drilon et al. NEJM 2018)

Methodologies and activities

- Constitute a Regional MTB (oncologist, pathologist, biologist, radiologist and others with a bioinformatic support) with monthly meetings
- Give a recommendation based on the specific molecular alteration
- Physician decision to follow or not to MTB recommendation
- Train an healthcare professional «navigator» who facilitate drug access to the patients, finding a clinical trial (or off-label) in which he can be enrolled
- Descriptive statistical analysis

Project and application

- The project will last at least 3 years (1 year: to constitute the MTB and 2 years of observation)
- At the end of the study we will describe:
 - 1) the adherence to MTB recommendation
 - 2) The rate of patients enrolled in clinical trials
 - 3) Exploratory analysis on clinical outcomes (RR, PFS and OS) of patients who followed vs. not MTB recommendation